Skip to main content
An official website of the United States government

Publications by the TARGET Program

Acute Lymphoblastic Leukemia (ALL) 

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia
N Engl J Med. 2009 Jan 29;360(5):470-80. doi: 10.1056/NEJMoa0808253

JAK mutations in high-risk childhood acute lymphoblastic leukemia
Proc Natl Acad Sci USA. 2009 Jun 9;106(23):9414-8. doi: 10.1073/pnas.0811761106. Epub 2009 May 

Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia
Blood. 2010 Feb 18;115(7):1394-405. doi: 10.1182/blood-2009-05-218560

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
Blood. 2010 Jul 1;115(26):5312-21. doi: 10.1182/blood-2009-09-245944

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome
Blood. 2010 Dec 2;116(23):4874-84. doi: 10.1182/blood-2009-08-239681

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia
Nat Genet. 2011 Mar;43(3):237-41. doi: 10.1038/ng.763.

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group
Blood. 2011 Sep 15;118(11):3080-7. doi: 10.1182/blood-2011-03-341412.

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
Cancer Cell. 2012 Aug 14;22(2):153-66. doi: 10.1016/j.ccr.2012.06.005.

Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project
Blood. 2013 Jan 17;121(3):485-8. doi: 10.1182/blood-2012-04-422691.

The molecular genetic makeup of acute lymphoblastic leukemia
Hematology Am Soc Hematol Educ Program. 2012;2012:389-96. doi: 10.1182/asheducation-2012.1.389.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
N Engl J Med. 2014 Sep 11;371(11):1005-15. doi: 10.1056/NEJMoa1403088.

Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia
Nat Commun. 2015 Mar 19;6:6604. doi: 10.1038/ncomms7604.

The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909.

The genetic basis and cell of origin of mixed phenotype acute leukaemia
Nature. 2018 Oct;562(7727):373-379. doi: 10.1038/s41586-018-0436-0.

The genomic landscape of pediatric acute lymphoblastic leukemia
Nat Genet. 2022 Sep 1. doi: 10.1038/s41588-022-01159-z

Acute Myeloid Leukemia (AML)

Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse
Cancer Res. 2016 Apr 15;76(8):2197-205. doi: 10.1158/0008-5472.CAN-15-1015.

CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML
Blood. 2016 Jun 16;127(24):3094-8. doi: 10.1182/blood-2016-04-709899. 

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia
J Clin Oncol. 2017 Dec 10;35(35):3964-3977. doi: 10.1200/JCO.2017.74.7451.

Genomics in childhood acute myeloid leukemia comes of age
Nat Med. 2018 Jan 9;24(1):7-9. doi: 10.1038/nm.4469.

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Nat Med. 2018 Jan;24(1):103-112. doi: 10.1038/nm.4439.

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
Leukemia. 2019 Aug;33(8):1934-1943. doi: 10.1038/s41375-019-0402-3.

Predicting Complete Remission of Acute Myeloid Leukemia: Machine Learning Applied to Gene Expression
Cancer Inform. 2019 Mar 15;18:1176935119835544. doi: 10.1177/1176935119835544.

Altered Transcriptome in Pediatric AML Compared with Normal Hematopoiesis
Br J Cancer Res. 2020 Jun 4;3(3):415-422. doi: 10.31488/bjcr.154

Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia
Nat Commun. 2022 Sep 19;13(1):5487. doi: 10.1038/s41467-022-33244-6

Kidney Tumors – Wilms Tumor (WT)

Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors
Cancer Cell. 2015 Feb 9;27(2):286-97. doi: 10.1016/j.ccell.2015.01.003.

MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours
Nat Commun. 2015 Dec 4;6:10013. doi: 10.1038/ncomms10013.

Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group
Clin Cancer Res. 2016 Nov 15;22(22):5582-5591. doi: 10.1158/1078-0432.CCR-16-0985.

A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor
Nat Genet. 2017 Oct;49(10):1487-1494. doi: 10.1038/ng.3940. 

A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study
PLoS One. 2018 Dec 13;13(12):e0208936. doi: 10.1371/journal.pone.0208936.

Kidney Tumors – Clear Cell Sarcoma (CCSK)

TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney
Oncotarget. 2015 Jun 30;6(18):15828-41. doi: 10.18632/oncotarget.4682.

Kidney Tumors – Rhabdoid Tumor (RT) 

Genome-Wide Profiles of Extra-cranial Malignant Rhabdoid Tumors Reveal Heterogeneity and Dysregulated Developmental Pathways
Cancer Cell. 2016 Mar 14;29(3):394-406. doi: 10.1016/j.ccell.2016.02.009.

Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration
Cell Rep. 2019 Nov 19;29(8):2338-2354.e7. doi: 10.1016/j.celrep.2019.10.013. 

Neuroblastoma (NBL)

The genetic landscape of high-risk neuroblastoma
Nat Genet. 2013 Mar;45(3):279-84. doi: 10.1038/ng.2529. 

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Nat Genet. 2015 Aug;47(8):864-71. doi: 10.1038/ng.3333.

Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism
Nature. 2015 Dec 17;528(7582):418-21. doi: 10.1038/nature15540.

Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma
Cancer Discov. 2018 May;8(5):582-599. doi: 10.1158/2159-8290.CD-16-0861.

Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma
Oncogene. 2018 Oct;37(40):5451-5465. doi: 10.1038/s41388-018-0326-9.

Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma
Clin Cancer Res. 2018 Nov 15;24(22):5673-5684. doi: 10.1158/1078-0432.CCR-18-0599.

Osteosarcoma (OS)

Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma
Oncotarget. 2017 May 27;8(57):96738-96752. doi: 10.18632/oncotarget.18236.


Outcomes for children and adolescents with cancer: challenges for the twenty-first century
J Clin Oncol. 2010 May 20;28(15):2625-34. doi: 10.1200/JCO.2009.27.0421.

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Nature. 2018 Mar 15;555(7696):371-376. doi: 10.1038/nature25795.

Pan-Cancer Model Systems (MDLS)

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design
Cell Rep. 2019 Nov 5;29(6):1675-1689.e9. doi: 10.1016/j.celrep.2019.09.071.

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Publications by the TARGET Program was originally published by the National Cancer Institute.”